Videos

Margaret Park, MD, defines typical signs and symptoms of narcolepsy and differentiates between the 2 main types of disease.

The president and chief executive officer of The ALS Association provided insight on the availability of genetic testing for ALS and the organization’s efforts to increase access for the future. [WATCH TIME: 2 minutes]

Klaus Schmierer, MB BS, PhD, FRCP, concludes with advice for community physicians and neurologists who are managing patients with MS and COVID-19 or vaccinations.

Dr Schmierer discusses the general guideline vaccination recommendations for patients with MS.

The president and chief executive officer of The ALS Association highlighted a few of the major developments in the ALS field over the past decade, led by advances in technology. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending March 26, 2022. [WATCH TIME: 4 minutes]

The neurologist and assistant professor at the University of Toronto discussed the different valued biomarkers to assess Alzheimer disease and whether the introduction of retinal imaging changes clinician perception of the most valuable biomarkers. [WATCH TIME: 3 minutes]

The president and chief executive officer of The ALS Association discussed how prevention is being talked about in the ALS community and why it’s no longer a far-off reality. [WATCH TIME: 4 minutes]

Drs Laxman Bahroo and Sanjay Iyer discuss common challenges in identifying OFF episodes in Parkinson disease, the importance of patient education, and utilizing symptom tracking diaries.

Laxman Bahroo, DO, and Sanjay Iyer, MD, define OFF episodes in Parkinson disease and review motor and nonmotor symptoms in patients.

The senior investigator in the Neuromuscular and Neurogenetic Disorders of Childhood Section at NINDS shared his perspective on the data coming out of neuromuscular research and the promise of genetic medicine. [WATCH TIME: 2 minutes]

The president and chief executive officer of The ALS Association provided commentary on the most pertinent issues with managing patients with ALS and the ways to improve current treatment standards. [WATCH TIME: 4 minutes]

The president and chief executive officer of The ALS Association provided insight on how the organization is advancing the therapeutic pipeline of ALS agents for the foreseeable future. [WATCH TIME: 3 minutes]

The president and CEO of the Muscular Dystrophy Association spoke about the need for increased participation in neuromuscular disorder clinical trials and the rapid therapeutic progress the field is seeing. [WATCH TIME: 4 minutes]

The president and chief executive officer of The ALS Association expanded on the organization’s greatest goal—making ALS livable by 2030—and how it plans to work towards that over the next decade. [WATCH TIME: 3 minutes]

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers and clinical professor of neurology at UCLA discussed the lack of a more focused and specific approach to care for women with Parkinson disease. [WATCH TIME: 6 minutes]

ACNS Critical Care EEG Terminology 2021 is a series dedicated to teaching an understanding of the American Clinical Neurophysiology Society's terminology. Check back for new episodes featuring special guests in the field.

The neurologist and assistant professor at the University of Toronto provided perspective on the multiple different ways retinal imaging can alter and improve the efficiency of research for Alzheimer disease. [WATCH TIME: 2 minutes]

The division chief of neuromuscular disorders and vice-chair of research at Virginia Commonwealth University spoke to the ongoing success in the development of gene-mediated therapies and the challenges that come along with treating rare neuromuscular disease. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending March 19, 2022.

An expert delves into the different types of immune responses a patient with MS can have to COVID-19 vaccines if they are also on DMTs.

Dr Schmierer explains how the SARS-CoV-2 infection and COVID-19 pandemic have impacted treating patients with MS with DMTs.

Looking to the future of multiple sclerosis care, the panel of thought leaders pose important questions that remain to be answered in the research and treatment of multiple sclerosis.

Expert panelists review the viability of new treatments in development for multiple sclerosis.

Alberto Ascherio, MD, DrPH, addresses the range of latency periods for Epstein-Barr virus and the impact on onset multiple sclerosis.

Alberto Ascherio, MD, DrPH; Anne Cross, MD; and Michael Racke, MD, discuss implications for patient communication and other advances from bench to bedside.

The expert panelists comment on intervention efforts underway to address multiple sclerosis prevention and treatment.

A panel of experts probe the variations in immune response to Epstein-Barr virus in patients with multiple sclerosis.

Alberto Ascherio, MD, DrPH, highlights key risk factors leading to increased prevalence of multiple sclerosis.

Anne Cross, MD, and Michael Racke, MD, discuss how the immune system is primed in multiple sclerosis.